Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9809
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia in adults. Its pipeline portfolio includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist for pruritus in atopic dermatitis; VQW-765 (formerly AQW-051), an alpha-7 nicotinic acetylcholine receptor for CNS disorders; and VTR-297 (formerly Trichostatin A) for oncology indications. Vanda Pharmaceuticals is headquartered in Washington DC, the US.

Vanda Pharmaceuticals Inc (VNDA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Equity Offering 13
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Acquisition 21
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc – Key Competitors 22
Vanda Pharmaceuticals Inc – Key Employees 23
Vanda Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2018: Vanda Pharmaceuticals reports third quarter 2018 financial results 25
Aug 01, 2018: Vanda pharmaceuticals reports second quarter 2018 financial results 26
May 02, 2018: Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results 27
Feb 14, 2018: Vanda Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 28
Jan 07, 2018: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance 29
Nov 07, 2017: Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results 30
Aug 02, 2017: Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results 31
May 02, 2017: Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results 32
Feb 15, 2017: Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results 33
Jan 09, 2017: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance 34
Legal and Regulatory 35
Nov 01, 2018: Vanda receives FDA letter regarding corporate webpage 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc, Key Competitors 22
Vanda Pharmaceuticals Inc, Key Employees 23
Vanda Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • KPJ Healthcare Berhad (KPJ):企業の財務・戦略的SWOT分析
    Summary KPJ Healthcare Berhad (KPJ) is a healthcare service provider that offers medical services. The center offers services in the areas of anaesthesiology, cardiology and cardiothoracic surgery, child psychiatry, clinic pathology, occupational health services, orthopaedic and trauma surgery, diet …
  • Waste Management, Inc.:企業の戦略・SWOT・財務分析
    Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Exmar NV (EXM):企業の財務・戦略的SWOT分析
    Summary Exmar NV (Exmar) a subsidiary of Compagnie Maritime Belge SA, operates as a shipping and energy supply chain solutions provider. The company's service portfolio includes liquefied natural gas (LNG), offshore, liquid petroleum gas (LPG) and supporting services. Its LNG segment offers floating …
  • SAS AB:戦略・SWOT・企業財務分析
    SAS AB - Strategy, SWOT and Corporate Finance Report Summary SAS AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Astellas Pharma Inc (4503):製薬・医療:M&Aディール及び事業提携情報
    Summary Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, inf …
  • Novozymes AS (NZYM B):企業の財務・戦略的SWOT分析
    Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Southern Petrochemical Industries Corp Ltd (SPIC):企業の財務・戦略的SWOT分析
    Summary Southern Petrochemical Industries Corp Ltd (SPIC) is a chemical company that manufactures fertilizers for agriculture. The company offers products such as chemical fertilizer, organic and water soluble fertilizers, plant growth regulators, micro nutrients, and industrial products. Its chemic …
  • Nationale-Nederlanden Levensverzekering Maatschappij N.V.:企業の戦略・SWOT・財務情報
    Nationale-Nederlanden Levensverzekering Maatschappij N.V. - Strategy, SWOT and Corporate Finance Report Summary Nationale-Nederlanden Levensverzekering Maatschappij N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the co …
  • Fonterra Co-operative Group Ltd:戦略・SWOT・企業財務分析
    Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • GLG Life Tech Corp (GLG):企業の財務・戦略的SWOT分析
    GLG Life Tech Corp (GLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Allianz Group:企業のM&A・事業提携・投資動向
    Allianz Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allianz Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Colefax Group Plc:企業の戦略・SWOT・財務情報
    Colefax Group Plc - Strategy, SWOT and Corporate Finance Report Summary Colefax Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • VEON Ltd:企業の戦略・SWOT・財務情報
    VEON Ltd - Strategy, SWOT and Corporate Finance Report Summary VEON Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Yandex NV (YNDX):企業の財務・戦略的SWOT分析
    Yandex NV (YNDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dhamma Energy:電力:M&Aディール及び事業提携情報
    Summary Dhamma Energy (Dhamma) is an energy services company that develops, operates and invests in solar photovoltaic installations. The company's services cover the technical and financial studies, development and acquisition, construction and commissioning, and operation and maintenance stages of …
  • Apple Inc:企業のM&A・事業提携・投資動向
    Apple Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Apple Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • RayBiotech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary RayBiotech Inc (RayBiotech) is a life science company that provides proteins, antibodies and immunological kits. The company's product categories include antibody arrays, glycobiology arrays, protein arrays, phosphorylation arrays, elisa, functional assays, antibodies and custom recombinant …
  • Celsion Corp (CLSN):医療機器:M&Aディール及び事業提携情報
    Summary Celsion Corp (Celsion) is an oncology company that strives to develop a portfolio of new cancer treatments, including directed chemotherapies, RNA or DNA based therapies and immunotherapies. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), T …
  • Energias de Portugal SA:企業の発電所・SWOT分析2018
    Energias de Portugal SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Cobham plc:企業の戦略・SWOT・財務情報
    Cobham plc - Strategy, SWOT and Corporate Finance Report Summary Cobham plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆